By Louis Garguilo, Chief Editor, Outsourced Pharma


Try as I may, I can’t get Massimo Dominici to use the term “CDMO,” although that’s what we’re talking about.

At least I think that’s what we’re talking about.

Finally, he relents; instead of saying “partnerships” again, he references “CDMO 2.0” as a different breed of external organization, established to support cell and gene therapy (CGT) companies – a prelude partner before potentially utilizing larger, established CDMOs.

Continue reading